title: Prostate cancer: beta control your hormones.
abstract: Differentiation status influences the prognosis for localized prostate cancer. In this issue of Cancer Cell, Mak and coworkers describe a signaling pathway involving estrogen receptor beta (ERbeta) that governs whether prostate carcinoma cells maintain an epithelial phenotype or undergo epithelial-mesenchymal transition, suggesting that ERbeta would have prognostic or therapeutic value.
authors.affiliation: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. massimo_loda@dfci.harvard.edu
authors.forename: Massimo
authors.initials: M
authors.lastname: Loda
authors.forename: William G
authors.initials: WG
authors.lastname: Kaelin
mesh_terms: D001940:Breast / Q000254:growth & development; D004847:Epithelial Cells / Q000187:drug effects; D004967:Estrogens / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control*
chemical_list: D004967:Estrogens